Promising combo trial halted early – too few patients to draw conclusions

NCT ID NCT05317936

Terminated Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small early-phase trial tested whether adding pirtobrutinib to venetoclax could wipe out leftover cancer cells in people with CLL/SLL who still had detectable disease after venetoclax alone. Only 3 people enrolled before the study was terminated, so we cannot draw any reliable conclusions about safety or effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pirtobrutinib and venetoclax
What this could lead to: If it works, this combination could help people with CLL/SLL achieve deeper remission by wiping out leftover cancer cells after standard treatment.
What could go wrong: The trial was terminated early with only 3 participants, so we have very little data. It is too early to know if the combination is safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA SMALL LYMPHOCYTIC LYMPHOMA

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.